NCT00917267 trial results

Inclusion Criteria: * Have been diagnosed with type 2 diabetes. * Have suboptimal glycemic control as evidenced by an HbA1c between 7.1% and 11.0% inclusive. * Have a body mass index (BMI) of \>21 kg/m2 and \<35 kg/m2, inclusive. * Have a history of stable body weight (not varying by \>5% for at least 90 days prior to study start). * Have been treated with a stable dose regimen of Met, SU, TZD, Met plus SU, Met plus TZD, or SU plus TZD for at least 90 days prior to study start. Exclusion Criteria: * Have any contraindication for the OAD(s) that they use. * Have a known allergy or hypersensitivity to exenatide BID, exenatide QW, or excipients contained in these agents. * Have received chronic \>14 consecutive days) systemic glucocorticoid therapy by oral, intravenous (IV), or intramuscular (IM) route or intra-articular steroid injection within 4 weeks prior to study start or are regularly treated with potent, inhaled steroids that are known to have a high rate of systemic absorption. * Have been treated with drugs that promote weight loss (for example, GLP-1 analogue, orlistat, sibutramine, phenylpropanolamine, or similar over-the-counter medications) within 90 days of study start. * Have been treated for \>2 weeks with any of the following excluded medications within 90 days prior to study start: * Insulin * Dipeptidyl peptidase (DPP)-4 inhibitors (for example, sitagliptin or vildagliptin) * Pramlintide acetate * Drugs that directly affect gastrointestinal motility, including, but not limited to: Reglan® (metoclopramide), Propulsid® (cisapride), and chronic macrolide antibiotics. * Have had prior exposure to exenatide * Have previously completed or withdrawn from this study or any other study investigating exenatide BID or QW. * Have received treatment within the last 30 days with a drug that has not received regulatory approval for any indication at the time of study entry. * Are currently enrolled in any other clinical study.